Breakdown of the blood-eye barrier in choroidal melanoma after proton beam radiotherapy.
Adult
Aged
Aqueous Humor
/ metabolism
Blood-Aqueous Barrier
/ physiology
Choroid Neoplasms
/ diagnosis
Female
Fluorescein Angiography
Follow-Up Studies
Fundus Oculi
Humans
Male
Melanoma
/ diagnosis
Middle Aged
Photometry
/ methods
Proton Therapy
Retrospective Studies
Tomography, Optical Coherence
Treatment Outcome
Visual Acuity
Breakdown blood-aqueous barrier
Choroidal melanoma
Flare meter
Inflammatory response
Proton beam radiotherapy
Journal
Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie
ISSN: 1435-702X
Titre abrégé: Graefes Arch Clin Exp Ophthalmol
Pays: Germany
ID NLM: 8205248
Informations de publication
Date de publication:
Oct 2019
Oct 2019
Historique:
received:
04
04
2019
accepted:
02
07
2019
revised:
25
06
2019
pubmed:
14
7
2019
medline:
23
1
2020
entrez:
14
7
2019
Statut:
ppublish
Résumé
Irradiation of choroidal melanoma is a safe and globe preserving procedure. Chronic inflammatory processes and ischemia are the main reasons for secondary enucleation in the long run. The aim of this study was to determine whether intraocular inflammation and especially inflammatory response after proton beam therapy (PBT) is related to primary tumor characteristics such as height, tumor volume, and initial flare values. Twenty-six patients treated for uveal melanoma using PBT were included. All patients were examined for signs of inflammation using laser flare photometry (LFP). Each examination included assessment of the melanoma and fellow eye (which acted as the control) and imaging of the melanoma. Significant differences of flare values between melanoma eyes and control group were found both at baseline (median 17.65 ph/ms (min 4, max 37.10), 7.45 ph/ms (min 0.80, max 16.40), respectively) and during follow-up (median 21.45 ph/ms (min 4.5, max 70.90); 6.05 ph/ms (min 2.40, max 16.40), respectively) (p < 0.001, Wilcoxon test). Flare values in melanoma eyes increased significantly after PBT (p = 0.005, Wilcoxon test) and after a follow-up of 94 days (median, 7-420 days). Flare values of the control group did not change (p = 0.946, Wilcoxon test). The increase of flare values correlated significantly with maximum tumor height and volume (Spearman-Rho 0.633, p = 0.001 and 0.519, p = 0.007, respectively). LFP has proven to show significantly higher flare values in melanoma eyes as compared with the control group and provides data on the course of the inflammatory response after treatment. It may ease treatment planning both at baseline and during follow-up.
Identifiants
pubmed: 31300898
doi: 10.1007/s00417-019-04413-z
pii: 10.1007/s00417-019-04413-z
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2323-2328Références
Arch Ophthalmol. 1979 Jul;97(7):1311-4
pubmed: 313204
Ophthalmologica. 1999;213(3):194-6
pubmed: 10202294
Eur J Ophthalmol. 2013 May-Jun;23(3):399-409
pubmed: 23483500
Am J Ophthalmol. 2015 Oct;160(4):628-36
pubmed: 26133249
Br J Ophthalmol. 2014 Jun;98(6):775-9
pubmed: 24568869
Arch Ophthalmol. 2006 Dec;124(12):1684-93
pubmed: 17159027
Am J Ophthalmol. 2017 Jun;178:94-100
pubmed: 28365241
Phys Med Biol. 2001 Mar;46(3):671-86
pubmed: 11277216
Eye (Lond). 2013 Feb;27(2):163-71
pubmed: 23196647
Ocul Oncol Pathol. 2014 Oct;1(1):24-33
pubmed: 27175359
Br J Ophthalmol. 2001 Nov;85(11):1305-8
pubmed: 11673294
Eur J Ophthalmol. 2011 Nov-Dec;21(6):796-801
pubmed: 21445839
Jpn J Ophthalmol. 2017 Jan;61(1):21-42
pubmed: 27888376
Phys Med Biol. 2002 Feb 21;47(4):593-613
pubmed: 11900193
Am J Ophthalmol. 2003 Jul;136(1):180-2
pubmed: 12834689
Invest Ophthalmol Vis Sci. 2001 Aug;42(9):2085-93
pubmed: 11481276
Arch Ophthalmol. 2006 Oct;124(10):1428-34
pubmed: 17030710
Invest Ophthalmol Vis Sci. 2012 Oct 01;53(11):6748-55
pubmed: 22930720
Eur J Ophthalmol. 2017 Aug 30;27(5):596-600
pubmed: 28218368
Ophthalmology. 2015 May;122(5):1023-9
pubmed: 25687025
Ophthalmology. 2010 May;117(5):1013-23
pubmed: 20097428
Am J Ophthalmol. 1994 Apr 15;117(4):521-8
pubmed: 8154537
Br J Ophthalmol. 1995 Apr;79(4):354-7
pubmed: 7742283
Graefes Arch Clin Exp Ophthalmol. 2016 Jul;254(7):1379-85
pubmed: 26960442